“我们明天还要来看机器人”！中国机器人广交会上实力“圈粉”，海外采购商挤爆展台

Core Insights - The 137th Canton Fair showcased a vibrant atmosphere, particularly in the newly established service robot exhibition area, attracting significant attention from international buyers [2][10] - Various types of robots were displayed, including humanoid, inspection, exoskeleton, coffee, cleaning, companion, medical, catering, and guiding robots, highlighting China's advancements in robotics [2][10] Group 1: Humanoid Robots - Humanoid robots became the star attraction, with companies like Magic Atom showcasing a "no-human booth" where the staff was entirely composed of humanoid robots [3] - The humanoid robot "Xiaomai" demonstrated advanced capabilities, including walking, running, and carrying loads of up to 40 kilograms, with a maximum operational endurance of 5 hours [3][4] Group 2: Industrial Applications - Companies like Ligong Industrial presented robots designed for factory applications, with a focus on international markets such as Europe and Southeast Asia, indicating a growing demand for automation in these regions [6] - The "Lideng D1" robot gained popularity for its precision in performing complex tasks, showcasing the technological advancements in robotic capabilities [6] Group 3: Medical and Daily Life Robots - The "Kuntuo Orthopedic Surgery Robot" demonstrated its capabilities in performing surgeries with high precision, having completed over 4,000 surgeries across various challenging environments [7] - The "Therapeutic Robot" developed by Aobo integrates traditional Chinese medicine techniques, attracting interest from international buyers unfamiliar with such technology [8] Group 4: Market Dynamics - The Canton Fair highlighted a "dual-direction" global supply-demand dynamic, with many international buyers actively seeking innovative products despite the backdrop of a trade war initiated by the U.S. [10] - Companies expressed confidence in their ability to navigate market challenges due to a well-established domestic market and a complete industrial chain in China [11]